Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype

Cancer Research

Volumn 65, Issue 23, 2005, Pages 10700-10708

  Libertini, Stephen J ^a,b   Robinson, Brian S ^a   Dhillon, Navdeep K ^a   Glick, Danielle ^a   George, Michael ^a   Dandekar, Satya ^a   Gregg, Jeffrey P ^a   Sawai, Earl ^a   Mudryj, Maria ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; CALPAIN II; CALPASTATIN; CYCLIN E; FOCAL ADHESION KINASE; PROTEIN KINASE P60; PROTEIN P53; PROTEINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; BREAST NEOPLASMS; CALPAIN; CELL LINE, TUMOR; CYCLIN E; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; ISOENZYMES; MICE; NEOPLASM METASTASIS; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 28244450957     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1666     Document Type: Article

References (54)

1. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994;54:380-5.
2. Kitahara K, Yasui W, Kuniyasu H, et al. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995;62:25-8.
3. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998;92: 770-7.
4. Marone M, Scambia G, Giannitelli C, et al. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer 1998;75:34-9.
5. Sakaguchi T, Watanabe A, Sawada H, et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 1998;82:1238-43.
6. Fukuse T, Hirata T, Naiki H, et al. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000;60:242-4.
7. Xiangming C, Natsugoe S, Takao S, et al. The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer 2000;89:1214-9.
8. Hedberg Y, Davoodi E, Ljungberg B, Roos G, Landberg G. Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int J Cancer 2002;102:601-7.
9. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
10. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 2003;22:4898-904.
11. Loden M, Stighall M, Nielsen NH, et al. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002;21:4680-90.
12. Porter DC, Zhang N, Danes C, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21: 6254-69.
13. Akli S, Zheng PJ, Multani AS, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198-208.
14. Bales E, Mills L, Milam N, et al. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 2005;65:692-7.
15. Wang XD, Rosales JL, Magliocco A, Gnanakumar R, Lee KY. Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. Oncogene 2003;22: 769-74.
16. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003;83:731-801.
17. Cooray P, Yuan Y, Schoenwaelder SM, Mitchell CA, Salem HH, Jackson SP. Focal adhesion kinase (pp125FAK) cleavage and regulation by calpain. Biochem J 1996;318: 41-7.
18. Stabach PR, Cianci CD, Glantz SB, Zhang Z, Morrow JS. Site-directed mutagenesis of αII spectrin at codon 1175 modulates its mu-calpain susceptibility. Biochemistry 1997;36:57-65.
19. Franco SJ, Rodgers MA, Perrin BJ, et al. Calpain-mediated proteolysis of talin regulates adhesion dynamics. Nat Cell Biol 2004;6:977-83.
20. Yamaguchi R, Maki M, Hatanaka M, Sabe H. Unphosphorylated and tyrosine-phosphorylated forms of a focal adhesion protein, paxillin, are substrates for calpain II in vitro: implications for the possible involvement of calpain II in mitosis-specific degradation of paxillin. FEBS Lett 1994;356:114-6.
21. Rios-Doria J, Day KC, Kuefer R, et al. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 2003;278:1372-9.
22. Rios-Doria J, Kuefer R, Ethier SP, Day ML. Cleavage of β-catenin by calpain in prostate and mammary tumor cells. Cancer Res 2004;64:7237-40.
23. Oda A, Druker BJ, Ariyoshi H, Smith M, Salzman EW. pp60src is an endogenous substrate for calpain in human blood platelets. J Biol Chem 1993;268:12603-8.
24. Kubbutat MH, Vousden KH. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 1997;17:460-8.
25. Pariat M, Carillo S, Molinari M, et al. Proteolysis by calpains: a possible contribution to degradation of p53. Mol Cell Biol 1997;17:2806-15.
26. Hirai S, Kawasaki H, Yaniv M, Suzuki K. Degradation of transcription factors. c-Jun and c-Fos, by calpain. FEBS Lett 1991;287:57-61.
27. Dhillon NK, Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 2002;21:4626-34.
28. Dhillon NK, Mudryj M. Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells. Genes Immun 2003;4:336-42.
29. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
30. Jessen KA, Liu SY, Tepper CG, et al. Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin, Breast Cancer Res 2004;6:R157-69.
31. Hata A, Ohno S, Akita Y, Suzuki K. Tandemly reiterated negative enhancer-like elements regulate transcription of a human gene for the large subunit of calcium-dependent protease. J Biol Chem 1989;264: 6404-11.
32. Wang KK, Posmantur R, Nadimpalli R, et al. Caspase-mediated fragmentation of calpain inhibitor protein calpastatin during apoptosis. Arch Biochem Biophys 1998;356:187-96.
33. Webster MA, Hutchinson JN, Rauh MJ, et al. Requirement for both She and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 1998;18:2344-59.
34. Elce JS, Hegadorn C, Arthur JS. Autolysis, Ca2+ requirement, and heterodimer stability in m-calpain. J Biol Chem 1997;272:11268-75.
35. Swanson C, Ross J, Jackson PK. Nuclear accumulation of cyclin E/Cdk2 triggers a concentration-dependent switch for the destruction of p27Xic1. Proc Natl Acad Sci USA 2000;97:7796-801.
36. Geng Y, Eaton EN, Picon M, et al. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 1996;12:1173-80.
37. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
38. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998;18:753-61.
39. Tompa P, Buzder-Lantos P, Tantos A, et al. On the sequential determinants of calpain cleavage. J Biol Chem 2004;279:20775-85.
40. Elvira M, Diez JA, Wang KK, Villalobo A. Phosphorylation of connexin-32 by protein kinase C prevents its proteolysis by mu-calpain and m-calpain. J Biol Chem 1993;268:14294-300.
41. Shen J, Channavajhala P, Seldin DC, Sonenshein GE. Phosphoryiation by the protein kinase CK2 promotes calpain-mediated degradation of IκBα. J Immunol 2001;167:4919-25.
42. Ilic D, Furuta Y, Kanazawa S, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995;377:539-44.
43. Carragher NO, Westhoff MA, Fincham VJ, Schaller MD, Frame MC. A novel role for FAX as a protease-targeting adaptor protein: regulation by p42 ERK and Src. Curr Biol 2003;13:1442-50.
44. Carragher NO, Westhoff MA, Riley D, et al. v-Src-induced modulation of the calpain-calpastatin proteolytic system regulates transformation. Mol Cell Biol 2002;22:257-69.
45. Weng Z, Taylor JA, Turner CE, Brugge JS, Seidel-Dugan C. Detection of Src homology 3-binding proteins, including paxillin, in normal and v-Src-transformed Balb/c 3T3 cells. J Biol Chem 1993;268: 14956-63.
46. Xu L, Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. J Biol Chem 2004;279:53683-90.
47. Mamoune A, Luo JH, Lauffenburger DA, Wells A. Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res 2003;63:4632-40.
48. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE. Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-α that can be inhibited by the tumor suppressor PTEN. Oncogene 2001;20:1287-99.
49. Glading A, Chang P, Lauffenburger DA, Wells A. Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J Biol Chem 2000;275:2390-8.
50. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
51. Shiba E, Kambayashi JI, Sakon M. et al, Ca2+ dependent neutral protease (calpain) activity in breast cancer tissue and estrogen receptor status. Breast Cancer 1996;3:13-7.
52. Lakshmikuttyamma A, Selvakumar P, Kanthan R, Kanthan SC, Sharma RK. Overexpression of m-calpain in human colorectal adenocarcinomas. Cancer Epidemiol Biomarkers Prev 2004;13:1604-9.
53. Braun C, Engel M, Seifert M, et al. Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type, Int J Cancer 1999;84:6-9.
54. Sriuranpong V, Mutirangura A, Gillespie JW, et al. Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays. Clin Cancer Res 2004;10: 4944-58.